Individual Patient Compassionate Use of Mirdametinib

Conditions:   Neurofibromatosis Type 1-Associated Plexiform Neurofibromas;   Histiocytic Neoplasm;   Other MAP-K Pathway Driven Diseases Intervention:   Drug: Mirdametinib (MEK Inhibitor) Sponsor:   SpringWorks Therapeutics, Inc. Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials